Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Objective This study investigates the positivity and relevance of non-criteria antiphospholipid antibodies (aPLs) with clinical phenotypes in patients highly suspected of or diagnosed with antiphospholipid antibody syndrome (APS). Methods Outpatient cases were included from a prospectively-maintained database, and patients were grouped into APS (n = 168), seronegative APS (SNAPS, n = 9), those meeting the diagnostic criteria for clinical events without laboratory results (only event, n = 15), those that had aPLs positivity without clinical manifestations (asymptomatic APA, n = 39), and healthy controls (n = 88). Criteria aPLs results and APS-related clinical features were extracted. Sixteen non-criteria aPLs were tested and analyzed. Results LA, aCL, and aβ2GpI were positive in 84.5%, 61.3%, and 74.4% of APS patients, and 61.5%, 59.0%, and 74.4% of asymptomatic APA patients. In patients negative for criteria serological tests, 23 out of 24 were positive for at least 1 non-criteria aPLs. Triple-positive patients also had significantly higher tests of some aPLs in comparison with other groups. Stroke was associated with anti-phosphatidyl-inositol (aPI) IgG and anti-phosphatidyl-glycerol (aPG) IgG. Late embryonic loss correlated with aPI IgM, and premature birth/eclampsia was associated with aPI IgG and aPG IgG. There were also positive associations between heart valve lesions and anti-phosphatidylserine–prothrombin (PS/PT) IgM, APS nephropathy and anti-phosphatidyl-choline (aPC) IgG or aPS/PT IgG, and livedo reticularis and anti-phosphatidyl-ethanolamine (aPE) IgM. Conclusion The prevalence of non-criteria aPLs differed from diagnostic biomarkers in patients diagnosed with or suspected of APS. Detection of aPLs provided additive value in the evaluation of APS-related clinical manifestations.
Objective This study investigates the positivity and relevance of non-criteria antiphospholipid antibodies (aPLs) with clinical phenotypes in patients highly suspected of or diagnosed with antiphospholipid antibody syndrome (APS). Methods Outpatient cases were included from a prospectively-maintained database, and patients were grouped into APS (n = 168), seronegative APS (SNAPS, n = 9), those meeting the diagnostic criteria for clinical events without laboratory results (only event, n = 15), those that had aPLs positivity without clinical manifestations (asymptomatic APA, n = 39), and healthy controls (n = 88). Criteria aPLs results and APS-related clinical features were extracted. Sixteen non-criteria aPLs were tested and analyzed. Results LA, aCL, and aβ2GpI were positive in 84.5%, 61.3%, and 74.4% of APS patients, and 61.5%, 59.0%, and 74.4% of asymptomatic APA patients. In patients negative for criteria serological tests, 23 out of 24 were positive for at least 1 non-criteria aPLs. Triple-positive patients also had significantly higher tests of some aPLs in comparison with other groups. Stroke was associated with anti-phosphatidyl-inositol (aPI) IgG and anti-phosphatidyl-glycerol (aPG) IgG. Late embryonic loss correlated with aPI IgM, and premature birth/eclampsia was associated with aPI IgG and aPG IgG. There were also positive associations between heart valve lesions and anti-phosphatidylserine–prothrombin (PS/PT) IgM, APS nephropathy and anti-phosphatidyl-choline (aPC) IgG or aPS/PT IgG, and livedo reticularis and anti-phosphatidyl-ethanolamine (aPE) IgM. Conclusion The prevalence of non-criteria aPLs differed from diagnostic biomarkers in patients diagnosed with or suspected of APS. Detection of aPLs provided additive value in the evaluation of APS-related clinical manifestations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.